Search alternatives:
significantly improve » significantly improved (Expand Search)
improve decrease » improve disease (Expand Search), improved urease (Expand Search), improves disease (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search), fold increases (Expand Search)
significantly improve » significantly improved (Expand Search)
improve decrease » improve disease (Expand Search), improved urease (Expand Search), improves disease (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search), fold increases (Expand Search)
-
1
-
2
Phosphorylation as an Effective Tool to Improve Stability and Reduce Toxicity of Antimicrobial Peptides
Published 2024“…Among them, W<sub>3</sub>BipY<sub>8</sub>-P stood out as the most promising peptide, exhibiting similar antibacterial activity as its unphosphorylated analog W<sub>3</sub>BipY<sub>8</sub> but with significantly reduced hemolytic activity (19-fold decrease), cytotoxicity (3.3-fold decrease), and an extended serum half-life 6.3 times longer than W<sub>3</sub>BipY<sub>8</sub>. …”
-
3
-
4
Summary of post-treatment disease course measures from MDMA-AT publications.
Published 2025Subjects: -
5
-
6
Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.
Published 2025Subjects: -
7
-
8
-
9
-
10
Summary of post-treatment disease course measures from off-label medications clinical trials.
Published 2025Subjects: -
11
Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.
Published 2025Subjects: -
12
Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.
Published 2025Subjects: -
13
Summary of post-treatment disease course measures from clinical trials with psychotherapies.
Published 2025Subjects: -
14
-
15
-
16
Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.
Published 2025Subjects: -
17
-
18
-
19
-
20